Anti-Atherosclerosis Agents Targeting Sphingosine Kinase

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$219,476.00
Award Year:
2006
Program:
SBIR
Phase:
Phase I
Contract:
1R43HL083765-01A1
Award Id:
81125
Agency Tracking Number:
HL083765
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
PO BOX 916, HERSHEY, PA, 17033
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
LYNN MAINES
() -
Business Contact:
CHARLES SMITH
(843) 792-3420
cdsmith@apogee-biotech.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Principal Investigator/Program Director: French, Kevin J. Abstract: The long-term goal of this program is to develop inhibitors of human sphingosine kinase (SK) that are effective as therapeutic agents. Because of its critical role in sphingolipid metabolism, we have focused on SK as an innovative molecular target for the development of new drugs for the treatment of atherosclerosis. Sphingolipids are being increasingly recognized as key mediators of cell proliferation, apoptosis and differentiation. In particular, SK is a critical regulator of vascular smooth muscle, endothelial cells, and inflammatory cells that are of central importance in atherosclerosis. Therefore, we hypothesize that SK is a key molecular target for the development of new anti-atherosclerotic drugs. In spite of accumulating evidence for a pivotal role of SK in the regulation of vascular inflammatory processes, pharmacological inhibition of SK is an untested means of preventing and/or treating atherosclerosis. This is largely due to the heretofore lack of pharmacologically useful SK inhibitors. To overcome this problem, we have recently identified novel inhibitors of human SK. These compounds are more potent than any other known SK inhibitor, and do not compete for the ATP binding site of the enzyme. We hypothesize that these SK inhibitors can be used to attenuate the atherosclerotic process, and will conduct the following proof-of-principle studies during Phase I of this project: 1). To determine the in vitro effects of these SK inhibitors on signaling cascades that contribute to atherosclerosis. Each SK inhibitor will be tested in several mechanism-based assays including: proliferation, apoptosis, sphingosine 1-phosphate generation, and induction of adhesion molecules. 2). To evaluate the therapeutic efficacies of SK inhibitors in a rodent model of atherosclerosis. The apoE-deficient mouse will be used as a model for atherosclerosis. Each SK inhibitor will be tested for efficacy in reducing aortic lesions, and effects on circulating inflammatory cytokines and sphingolipids.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government